Major Indian generic-drug maker selling generics, APIs and biosimilars across the US, Europe, Russia/CIS and India.
Major Indian generic-drug maker selling generics, APIs and biosimilars across the US, Europe, Russia/CIS and India.
North America, mainly generics sold to wholesalers, pharmacy chains and purchasing groups, is the largest region, and profit swings come from a few limited-competition generic launches, since prices on older products fall as competitors enter. Active ingredients sold to other drugmakers add a smaller line. The Reddy family and associates are the promoters.
In one line: India's Teva Pharmaceutical.
Moat: narrow (scale, regulatory licence, distribution). Large vertically integrated API-to-formulation manufacturing and broad regulatory filings.
Headquarters: Hyderabad, India · Founded: 1984 · Employees: 27,527
Size Dr. Reddy's Laboratories (DRREDDY.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $12.5B, the 94th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,398 on 18 Nov 2026.
Performance Over six months the shares gained 4.7%, against +8.3% for the median peer and +3.8% for the India market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue fell 3.6% over the last twelve months (peer median +14.6%); the operating margin is 8.9% (peer median 21.5%).
Valuation It trades at 32.0× forward earnings against a peer median of 27.6× (8th most expensive of 19).
Price implies For today's price to make sense, revenue must grow about 31% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +19 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.5 points below its cost of capital (10.1% WACC).
Next results Next results expected around 22 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹330B | ₹336B | ₹326B | ₹279B | ₹246B |
| Revenue growth | — | +3% | +17% | +14% | — |
| Gross profit | ₹151B | ₹165B | ₹180B | ₹156B | ₹133B |
| EBITDA | ₹50.8B | ₹67.4B | ₹86.6B | ₹78.7B | ₹64.9B |
| Net income | ₹28.0B | ₹42.9B | ₹56.5B | ₹55.7B | ₹45.1B |
| Free cash flow | ₹11.7B | ₹30.5B | ₹18.8B | ₹28.5B | ₹46.5B |
| Capital expenditure | ₹26.2B | ₹38.4B | ₹34.4B | ₹27.4B | ₹18.9B |
| Total debt | ₹72.3B | ₹77.3B | ₹46.8B | ₹20.0B | ₹13.5B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Dr. Reddy's Laboratories DRREDDY.NS | $12.5B | +5% | -4% | 9% | 32.0× | 30.7% |
| Sun Pharmaceutical Industries SUNPHARMA.NS | $48.0B | -1% | +12% | 23% | 36.0× | 28.7% |
| Cipla CIPLA.NS | $12.2B | +1% | -1% | 13% | 29.1× | 28.4% |
| Lupin LUPIN.NS | $9.67B | -14% | +24% | 24% | 21.0× | 8.8% |
| Teva Pharmaceutical Industries Limited Sponsored ADR TEVA | $49.3B | +23% | -4% | 19% | 15.0× | 10.5% |
| Viatris VTRS | $23.3B | +23% | +5% | 11% | 7.5× | 11.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | DRREDDY.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +12.5% | +5.7% | 5th highest of 21 |
| 6-month return | +4.7% | +8.3% | 9th lowest of 21 |
| Distance from 52-week high | -1.2% | -7.2% | highest of 21 |
| Revenue growth (TTM) | -3.6% | +14.6% | 2nd lowest of 20 |
| Operating margin | 8.9% | 21.5% | 5th lowest of 20 |
| Forward P/E | 32.0× | 27.6× | 8th most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 30.7% | 1.1% | 5th most demanding of 16 |
| Growth delivered (Del g) | +12.1% | +12.6% | 7th lowest of 16 |
| Hurdle (Req g minus delivered) | +18.6 pp | -11.4 pp | 4th most demanding of 16 |
| ROIC minus cost of capital | -4.5 pp | +5.6 pp | 4th lowest of 19 |
| EV / EBITDA | 22.9× | 16.0× | 6th most expensive of 14 |
| Net debt / EBITDA | -0.1× | 0.7× | 6th least indebted of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Dr. Reddy's Laboratories DRREDDY.NS | India | $12.5B | +5% | -4% | 9% | 32.0× | 30.7% | +12.1% |
| Sbp 1177.HK | Hong Kong | $12.2B | +5% | +15% | 30% | 17.5× | -5.7% | +5.4% |
| Zydus Lifesciences ZYDUSLIFE.NS | India | $12.8B | +18% | +24% | 17% | 30.0× | n/a | n/a |
| Sichuan Kelun-Biotech Biopharmaceutical 6990.HK | Hong Kong | $13.0B | -1% | +44% | -38% | 1,176.1× | 55.3% | +33.6% |
| Recordati REC.MI | Italy | $12.0B | +3% | +8% | 30% | 16.6× | 1.1% | +12.6% |
| Zhangzhou Pientzehuang Pharmaceutical 600436.SS | China | $11.6B | -4% | -19% | 19% | 40.7× | 24.9% | +6.8% |
| Mankind Pharma MANKIND.NS | India | $11.6B | +5% | +13% | 21% | 44.4× | 28.6% | +18.1% |
| Laurus Labs LAURUSLABS.NS | India | $13.4B | +73% | +23% | 24% | 76.4× | 51.2% | +7.3% |
| Repligen RGEN | United States | $11.0B | +55% | +14% | 9% | 71.0× | 56.9% | +15.0% |
| Ipsen IPN.PA | France | $14.8B | +1% | +14% | 30% | 10.8× | -6.7% | +7.2% |
| Sichuan Biokin Pharmaceutical 688506.SS | China | $14.9B | -7% | +14% | -43% | n/a | n/a | n/a |
| Yunnan Baiyao 000538.SZ | China | $15.0B | +11% | +5% | 11% | 18.3× | -0.2% | +4.7% |
| PharmaEssentia 6446.TW | Taiwan | $15.0B | +67% | +78% | 40% | 31.9× | 23.7% | +94.8% |
| TG Therapeutics TGTX | United States | $9.99B | +66% | +69% | 21% | 25.2× | 43.0% | +426.7% |
| Orion ORNAV.HE | Finland | $15.7B | +41% | +34% | 38% | 23.6× | -6.2% | +11.7% |
| Pharmaron Beijing 300759.SZ | China | $9.90B | +52% | +18% | 14% | 36.8× | n/a | n/a |
| Jazz Pharmaceuticals Public JAZZ | United States | $15.9B | +4% | +13% | 25% | 9.3× | -2.8% | +12.5% |
| Swedish Orphan Biovitrum SOBI.ST | Sweden | $16.1B | +6% | +15% | 30% | 24.1× | -2.1% | +13.1% |
| Spyre Therapeutics SYRE | United States | $9.64B | +41% | n/a | n/a | n/a | n/a | n/a |
| Exelixis EXEL | United States | $16.7B | +37% | +9% | 40% | 17.7× | -3.8% | +18.6% |
| Madrigal Pharmaceuticals MDGL | United States | $9.25B | -22% | +93% | -11% | 81.5× | n/a | n/a |